238 related articles for article (PubMed ID: 21640744)
1. AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group.
Zhong L; Shen H; Huang C; Jing H; Cao D
Toxicol Appl Pharmacol; 2011 Aug; 255(1):40-7. PubMed ID: 21640744
[TBL] [Abstract][Full Text] [Related]
2. Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3.
Hofman J; Malcekova B; Skarka A; Novotna E; Wsol V
Toxicol Appl Pharmacol; 2014 Aug; 278(3):238-48. PubMed ID: 24832494
[TBL] [Abstract][Full Text] [Related]
3. Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture.
Kuffel MJ; Reid JM; Ames MM
Cancer Chemother Pharmacol; 1992; 30(1):51-7. PubMed ID: 1586980
[TBL] [Abstract][Full Text] [Related]
4. Cancer biomarker AKR1B10 and carbonyl metabolism.
Balendiran GK; Martin HJ; El-Hawari Y; Maser E
Chem Biol Interact; 2009 Mar; 178(1-3):134-7. PubMed ID: 19028477
[TBL] [Abstract][Full Text] [Related]
5. Different cytotoxicity and metabolism of doxorubicin, daunorubicin, epirubicin, esorubicin and idarubicin in cultured human and rat hepatocytes.
Le Bot MA; Bégué JM; Kernaleguen D; Robert J; Ratanasavanh D; Airiau J; Riché C; Guillouzo A
Biochem Pharmacol; 1988 Oct; 37(20):3877-87. PubMed ID: 3190734
[TBL] [Abstract][Full Text] [Related]
6. Fibrates in the chemical action of daunorubicin.
Balendiran GK
Curr Cancer Drug Targets; 2009 May; 9(3):366-9. PubMed ID: 19442055
[TBL] [Abstract][Full Text] [Related]
7. In vitro evaluation of the reductive carbonyl idarubicin metabolism to evaluate inhibitors of the formation of cardiotoxic idarubicinol via carbonyl and aldo-keto reductases.
Bajraktari-Sylejmani G; Oster JS; Burhenne J; Haefeli WE; Sauter M; Weiss J
Arch Toxicol; 2024 Mar; 98(3):807-820. PubMed ID: 38175295
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting wild-type and C299S mutant AKR1B10; a homologue of aldose reductase upregulated in cancers.
Verma M; Martin HJ; Haq W; O'Connor TR; Maser E; Balendiran GK
Eur J Pharmacol; 2008 Apr; 584(2-3):213-21. PubMed ID: 18325492
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of AKR1B10-mediated metabolism of daunorubicin as a novel off-target effect for the Bcr-Abl tyrosine kinase inhibitor dasatinib.
Büküm N; Novotná E; Morell A; Želazková J; Laštovičková L; Čermáková L; Portillo R; Solich P; Wsól V
Biochem Pharmacol; 2021 Oct; 192():114710. PubMed ID: 34339712
[TBL] [Abstract][Full Text] [Related]
10. Purification and characterization of akr1b10 from human liver: role in carbonyl reduction of xenobiotics.
Martin HJ; Breyer-Pfaff U; Wsol V; Venz S; Block S; Maser E
Drug Metab Dispos; 2006 Mar; 34(3):464-70. PubMed ID: 16381663
[TBL] [Abstract][Full Text] [Related]
11. Cellular uptake and antiproliferative effects of therapeutic concentrations of idarubicin or daunorubicin and their alcohol metabolites, with or without cyclosporin A, in MDR1+ human leukemic cells.
Chiodini B; Bassan R; Barbui T
Leuk Lymphoma; 1999 May; 33(5-6):485-97. PubMed ID: 10342576
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of human anthracycline reductases by emodin - A possible remedy for anthracycline resistance.
Hintzpeter J; Seliger JM; Hofman J; Martin HJ; Wsol V; Maser E
Toxicol Appl Pharmacol; 2016 Feb; 293():21-9. PubMed ID: 26773812
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model.
Berg SL; Reid J; Godwin K; Murry DJ; Poplack DG; Balis FM; Ames MM
J Pediatr Hematol Oncol; 1999; 21(1):26-30. PubMed ID: 10029808
[TBL] [Abstract][Full Text] [Related]
14. Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention.
Yan R; Zu X; Ma J; Liu Z; Adeyanju M; Cao D
Int J Cancer; 2007 Nov; 121(10):2301-6. PubMed ID: 17597105
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacokinetics of new anthracyclines].
Robert J
Bull Cancer; 1988; 75(2):167-74. PubMed ID: 3282579
[TBL] [Abstract][Full Text] [Related]
16. Development of drug resistance is reduced with idarubicin relative to other anthracyclines.
Hargrave RM; Davey MW; Davey RA; Kidman AD
Anticancer Drugs; 1995 Jun; 6(3):432-7. PubMed ID: 7670142
[TBL] [Abstract][Full Text] [Related]
17. Comparative evaluation of the intracellular accumulation and DNA binding of idarubicin and daunorubicin in sensitive and multidrug-resistant human leukaemia K562 cells.
Bogush T; Robert J
Anticancer Res; 1996; 16(1):365-8. PubMed ID: 8615637
[TBL] [Abstract][Full Text] [Related]
18. Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin.
Bains OS; Grigliatti TA; Reid RE; Riggs KW
J Pharmacol Exp Ther; 2010 Dec; 335(3):533-45. PubMed ID: 20837989
[TBL] [Abstract][Full Text] [Related]
19. Effect of idarubicin and epirubicin on in vitro polymorphonuclear function: diminished superoxide radical formation compared to their parent compounds daunorubicin and doxorubicin.
Cairo MS; Toy C; Sender L; van de Ven C
J Leukoc Biol; 1990 Mar; 47(3):224-33. PubMed ID: 2155275
[TBL] [Abstract][Full Text] [Related]
20. Idarubicin DNA intercalation is reduced by MRP1 and not Pgp.
Smeets ME; Raymakers RA; Vierwinden G; Pennings AH; Boezeman J; Minderman H; de Witte TM
Leukemia; 1999 Sep; 13(9):1390-8. PubMed ID: 10482990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
